An orally studied octapeptide aimed at the gut's tight junctions.
Also known as: larazotide acetate · AT-1001
Part of the Foundational & therapeutic peptides cluster
Overview
Larazotide (larazotide acetate, AT-1001) is a synthetic eight-amino-acid peptide studied as a regulator of intestinal tight junctions, the seals between gut lining cells. It was investigated in celiac disease research. Its Phase 3 program was discontinued and it is not approved; this page is educational only.
Source & context
Biological / chemical source: Synthetic octapeptide
Primary research or clinical context: Investigational compound; Phase 3 program discontinued, not approved
Tight-junction target
Larazotide (GGVLVQPG) is designed to act at the gut epithelial barrier, where tight junctions control how much passes between cells. It is studied as an antagonist of zonulin-driven permeability, intended to keep junctions in their closed state. It is meant to act locally in the intestine rather than being absorbed systemically.
Development and status
Larazotide was studied mainly in celiac disease, but its sponsor announced discontinuation of a Phase 3 trial in 2022, and it has not been approved by Health Canada or the FDA. It remains an investigational compound. This summary describes the peptide and its research history and makes no therapeutic claims.
Sequence
One-letter sequence commonly cited for Larazotide (educational; isoforms and modifications may differ):
GGVLVQPG
Residues plotted ~100° apart around an α-helix — clustering of one color reveals an amphipathic face.
FAQ about Larazotide
What is Larazotide?+
Larazotide (larazotide acetate, AT-1001) is a synthetic eight-amino-acid peptide studied as a regulator of intestinal tight junctions, the seals between gut lining cells. It was investigated in celiac disease research. Its Phase 3 program was discontinued and it is not approved; this page is educational only.
Is Larazotide an approved medicine?+
Larazotide is discussed here as a research / educational topic. Investigational compound; Phase 3 program discontinued, not approved. This is not medical advice.
What is the typical length of Larazotide?+
Larazotide is commonly described as approximately 8 amino acids (Tight-junction regulator peptide).